DexCom (DXCM) to Release Earnings on Thursday

DexCom (NASDAQ:DXCM) is scheduled to be issuing its quarterly earnings data after the market closes on Thursday, October 24th. Analysts expect the company to announce earnings of $0.44 per share for the quarter. DexCom has set its Q3 2024 guidance at EPS and its FY 2024 guidance at EPS.Investors that wish to listen to the company’s conference call can do so using this link.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping the consensus estimate of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $1.04 billion. During the same period last year, the business posted $0.34 EPS. DexCom’s quarterly revenue was up 15.3% on a year-over-year basis. On average, analysts expect DexCom to post $2 EPS for the current fiscal year and $2 EPS for the next fiscal year.

DexCom Price Performance

Shares of DXCM stock opened at $73.08 on Wednesday. The stock has a market capitalization of $29.06 billion, a price-to-earnings ratio of 47.15, a P/E/G ratio of 2.16 and a beta of 1.18. The company has a current ratio of 2.82, a quick ratio of 2.48 and a debt-to-equity ratio of 1.00. DexCom has a twelve month low of $62.34 and a twelve month high of $142.00. The stock has a fifty day simple moving average of $70.03 and a two-hundred day simple moving average of $99.06.

Insider Activity

In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. In related news, EVP Sadie Stern sold 426 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total value of $29,457.90. Following the completion of the transaction, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at $5,217,436.65. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, COO Jacob Steven Leach sold 746 shares of the stock in a transaction that occurred on Monday, September 9th. The shares were sold at an average price of $69.15, for a total transaction of $51,585.90. Following the completion of the transaction, the chief operating officer now directly owns 264,915 shares of the company’s stock, valued at $18,318,872.25. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,824 shares of company stock worth $126,390 over the last 90 days. 0.30% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several brokerages have issued reports on DXCM. Barclays dropped their target price on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. StockNews.com downgraded shares of DexCom from a “buy” rating to a “hold” rating in a research note on Saturday, October 12th. JPMorgan Chase & Co. cut DexCom from an “overweight” rating to a “neutral” rating and dropped their target price for the company from $145.00 to $75.00 in a research report on Friday, July 26th. Morgan Stanley reduced their price target on DexCom from $120.00 to $75.00 and set an “equal weight” rating for the company in a research report on Friday, July 26th. Finally, Oppenheimer dropped their price objective on DexCom from $150.00 to $115.00 and set an “outperform” rating on the stock in a research report on Friday, July 26th. Seven research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom has an average rating of “Moderate Buy” and an average price target of $110.73.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.